AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

October 2, 2026 2:30 AM EDT

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC).

Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and... More